Page 453 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 22 Soft Tissue Sarcomas 431

231. Martano M, Morello E, Ughetto M, et al.: Surgery alone versus 250. Spugnini EP, Renaud SM, Buglioni S, et al.: Electrochemotherapy
surgery and doxorubicin for the treatment of feline injection-site with cisplatin enhances local control after surgical ablation of fibro-
sarcomas: a report on 69 cases, Vet J 170:84–90, 2005. sarcoma in cats: an approach to improve the therapeutic index of
VetBooks.ir 232. Cronin K, Page RL, Spodnick G, et al.: Radiation therapy and sur- 251. Knapp DW, Richardson RC, DeNicola DB, et al.: Cisplatin toxic-
highly toxic chemotherapy drugs, J Transl Med 9:152, 2011.
gery for fibrosarcoma in 33 cats, Vet Radiol Ultrasound 39:51–56,
ity in cats, J Vet Intern Med 1:29–35, 1987.
1998.
233. Bregazzi VS, LaRue SM, McNiel E, et al.: Treatment with a com- 252. Jourdier TM, Moste C, Bonnet MC, et al.: Local immunotherapy
bination of doxorubicin, surgery, and radiation versus surgery of spontaneous feline fibrosarcomas using recombinant poxviruses
and radiation alone for cats with injection-site sarcomas: 25 cases expressing interleukin 2 (IL2), Gene Ther 10:2126–2132, 2003.
(1995-2000), J Am Vet Med Assoc 218:547–550, 2001. 253. Jas D, Soyer C, De Fornel-Thibaud P, et al.: Adjuvant immuno-
234. Kobayashi T, Hauck ML, Dodge R, et al.: Preoperative radio- therapy of feline injection-site sarcomas with the recombinant
therapy for injection-site sarcoma in 92 cats, Vet Radiol Ultrasound canarypox virus expressing feline interleukine-2 evaluated in a
43:473–479, 2002. controlled monocentric clinical trial when used in association with
235. Eckstein C, Guscetti F, Roos M, et al.: A retrospective analysis of surgery and brachytherapy, Trials Vaccinol 4:1–8, 2015.
radiation therapy for treatment of feline vaccine-associated sar- 254. Jahnke A, Hirschberger J, Fischer C, et al.: Intra-tumoral gene
coma, Vet Comp Oncol 7:54–68, 2009. delivery of feIL-2, feIFN-gamma and feGM-CSF using magneto-
236. Mayer MN, Treuil PL, LaRue SM: Radiotherapy and surgery for fection as a neoadjuvant treatment option for feline fibrosarcoma:
feline soft tissue sarcoma, Vet Radiol Ultrasound 50:669–672, 2009. a phase I trial, J Vet Med A Physiol Pathol Clin Med 54:599–606,
237. Kleiter M, Tichy A, Willmann M, et al.: Concomitant liposomal 2007.
doxorubicin and daily palliative radiation therapy in advanced 255. H007.A Physiol Pathberger J, Jahnke A, et al: Neoadjuvant gene
feline soft tissue sarcomas, Vet Radiol Ultrasound 51:349–355, delivery of feline granulocyte-macrophage colony-stimulating fac-
2010. tor using magnetofection for the treatment of feline fibrosarcomas:
238. Nolan MW, Griffin LR, Custis JT, et al.: Stereotactic body radia- a phase I trial, J Gene Med 10:655–667, 2008.
tion therapy for treatment of injection-site sarcomas in cats: 11 256. Kent EM: Use of an immunostimulant as an aid in treatment and
cases (2008-2012), J Am Vet Med Assoc 15:526–531, 2013. management of fibrosarcoma in three cats, Fel Pract 21(13), 1993.
239. Williams LE, Banerji N, Klausner JS, et al.: Establishment of two 257. King GK, Yates KM, Greenlace PG, et al.: The effect of acemannan
injection-site feline sarcoma cell lines and determination of in vitro immunostimulant in combination with surgery and radiation ther-
chemosensitivity to doxorubicin and mitoxantrone, Am J Vet Res apy on spontaneous canine and feline fibrosarcomas, J Am Anim
62:1354–1357, 2001. Hosp Assoc 31:439–447, 1995.
240. Banerji N, Li X, Klausner JS, et al.: Evaluation of in vitro chemo- 258. Quintin-Colonna F, Devauchelle P, Fradelizi D, et al.: Gene ther-
sensitivity of injection-site feline sarcoma cell lines to vincristine apy of spontaneous canine melanoma and feline fibrosarcoma by
and paclitaxel, Am J Vet Res 63:728–732, 2002. intratumoral administration of histoincompatible cells expressing
241. Hill J, Lawrence J, Saba C, et al.: In vitro efficacy of doxorubicin human interleukin-2, Gene Ther 3:1104–1112, 1996.
and etoposide against a feline injection-site sarcoma cell line, Res 259. Giudice C, Stefanello D, Sala M, et al.: Feline injection-site sar-
Vet Sci 97:348–356, 2014. coma: recurrence, tumour grading and surgical margin status
242. Barber LG, Sorenmo KU, Cronin KL, et al.: Combined doxorubi- evaluated using the three-dimensional histological technique, Vet J
cin and cyclophosphamide chemotherapy for nonresectable feline 186:84–88, 2010.
fibrosarcoma, J Am Anim Hosp Assoc 36:416–421, 2000. 260. Hahn KA, Endicott MM, King GK, et al.: Evaluation of radiother-
243. Poirier VJ, Thamm DH, Kurzman ID, et al.: Liposome-encap- apy alone or in combination with doxorubicin chemotherapy for
sulated doxorubicin (Doxil) and doxorubicin in the treatment of the treatment of cats with incompletely excised soft tissue sarcomas:
injection-site sarcomas in cats, J Vet Intern Med 16:726–731, 2002. 71 cases (1989–1999), J Am Vet Med Assoc 231:742–745, 2007.
244. Saba CF, Vail DM, Thamm DH: Phase II clinical evaluation of 261. Porcellato I, Menchetti L, Brachelente C, et al.: Feline injection-site
lomustine chemotherapy for feline vaccine-associated sarcoma, Vet sarcoma: matrix remodeling and prognosis, Vet Pathol 54:204–211,
Comp Oncol 10:283–291, 2012. 2017.
245. Katayama R, Huelsmeyer MK, Marr AK, et al.: Imatinib mesylate 262. Dillon CJ, Mauldin GN, Baer KE: Outcome following surgical
inhibits platelet-derived growth factor activity and increases che- removal of nonvisceral soft tissue sarcomas in cats: 42 cases (1992-
mosensitivity in feline injection-site sarcoma, Cancer Chemother 2000), J Am Vet Med Assoc 227:1955–1957, 2005.
Pharmacol 54:25–33, 2004. 263. Macy DW: Current understanding of vaccination site-associated
246. Lawrence J, Saba C, Gogal R, et al.: Mastinib demonstrates anti- sarcomas in the cat, J Feline Med Surg 1:15–21, 1999.
proliferative and pro-apoptotic activity in primary and metastatic 264. Martano M, Morello E, Buracco P: Feline injection-site sarcoma:
feline injection-site sarcoma cells, Vet Comp Oncol 10:143–154, past, present and future perspectives, Vet J 1888:136–141, 2011.
2012. 265. Hendricks CG, Levy JK, Tucker SJ, et al.: Tail vaccination in cats:
247. Turek M, Gogal R, Saba C, et al.: Masitinib mesylate does not a pilot study, J Feline Med Surg 16:275–280, 2014.
enhance sensitivity to radiation in three feline injection-site sarcoma 266. Scott FW, Geissinger CM: Duration of immunity in cats vacci-
cell lines under normal growth conditions, Res Vet Sci 96:304–307, nated with an inactivated feline panleukopenia, herpesvirus, and
2014. calicivirus vaccine, Fel Pract 25(12), 1997.
248. Holtermann N, Kiupel M, Hirschberger J: The tyrosine kinase 267. Scott FW, Geissinger CM: Long-term immunity in cats vaccinated
inhibitor toceranib in feline injection-site sarcomas: efficacy and with an inactivated trivalent vaccine, Am J Vet Res 60:652–658,
side effects, Vet Comp Oncol 15:632–640, 2017. 1999.
249. Spugnini EP, Baldi A, Vincenzi B, et al.: Intraoperative versus post- 268. Jas D, Frances-Duvert V, Vernes D, et al.: Three-year duration
operative electrochemotherapy in high grade soft tissue sarcomas: a of immunity for feline herpesvirus and calicivirus evaluated in a
preliminary study in a spontaneous feline model, Cancer Chemother controlled vaccination-challenge laboratory trial, Vet Microbiol
Pharmacol 59:375–381, 2007. 177:123–131, 2015.